US Drug Recall Register
Class II · Moderate risk Terminated Initiated May 17, 2018 (8 years ago)

My Way

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Marketed Without an Approved NDA/ANDA: 2-pack configuration did not receive appropriate regulatory approval prior to release.

What was recalled

My Way (Levonorgestrel) Tablets TWO PACK, 1.5 mg each, packaged as 2 Treatments (Two 1.5mg Levonorgestrel Tablets) per carton, GAVIS Pharmaceuticals, A Lupin Group Company; Mfg. for Lupin Pharmaceuticals, Inc., Baltimore, MD 21202, UPC 3 43386-622-31 3.

Recalling firm
Lupin Pharmaceuticals Inc.
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0837-2018

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Levonorgestrel recalls

See all
Class II · Moderate risk Terminated

Lillow

Reason CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Cardinal Healthcare NDC 69238-1554-6 D-0187-2024
Class II · Moderate risk Terminated

Levonorgestrel and Ethinyl Estradiol Tablets USP

Reason Failed Content Uniformity Specifications: Out Of Specification test results observed for content uniformity.

Lupin Pharmaceuticals Inc. NDC 68180-857-11 D-1056-2020
Class II · Moderate risk Terminated

Fayosim

Reason Failed Impurities/Degradation Specifications: Out-of-specification results observed in related substance test (Any Other Individual Impurity and Total impurities) in Ethinyl Estradiol Tablets USP 0.01mg at 12 month long term stability study.

Lupin Pharmaceuticals Inc. NDC 68180-860-11 D-1057-2019
Class III · Low risk Terminated

Altavera Levonorgestrel and Ethinyl Estradiol Tablets

Reason Labeling: Not Elsewhere Classified: mislabeling of the Altavera generic name on the packaging component that may cause confusion.

Xiromed LLC NDC 70700-116-85 D-0016-2019